Synendos Therapeutics Company
Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of the brain.
The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need.
.png)
Employee Number:
11-50
Headquarters:
Allschwil, Basel-Landschaft, Switzerland, Europe
Founded Date:
2019-04-01
Industry:
Drug Discovery & Development
Super Industry:
Biopharma & Life Science Tools
Investors:
HTGF (High-Tech Gruenderfonds), Kurma Partners, Venture Kick, Ysios Capital, Z?rcher Kantonal Bank
Ipo Status:
private
City:
Allschwil
Region:
Basel-Landschaft
Country:
Switzerland
Founders:
Andrea Chicca, Jurg Gertsch, Simon Russell